- Home
- TLS vs XNCR Comparison
TLS vs XNCR Comparison
Compare TLS & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- XNCR
- Stock Information
- Founded
- TLS 1969
- XNCR 1997
- Country
- TLS United States
- XNCR United States
- Employees
- TLS N/A
- XNCR N/A
- Industry
- TLS EDP Services
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- TLS Technology
- XNCR Health Care
- Exchange
- TLS Nasdaq
- XNCR Nasdaq
- Market Cap
- TLS 508.2M
- XNCR 547.8M
- IPO Year
- TLS 2020
- XNCR 2013
- Fundamental
- Price
- TLS $6.94
- XNCR $14.77
- Analyst Decision
- TLS Hold
- XNCR Buy
- Analyst Count
- TLS 4
- XNCR 11
- Target Price
- TLS $4.83
- XNCR $22.20
- AVG Volume (30 Days)
- TLS 845.1K
- XNCR 1.3M
- Earning Date
- TLS 11-11-2025
- XNCR 11-05-2025
- Dividend Yield
- TLS N/A
- XNCR N/A
- EPS Growth
- TLS N/A
- XNCR N/A
- EPS
- TLS N/A
- XNCR N/A
- Revenue
- TLS $116,739,000.00
- XNCR $146,929,000.00
- Revenue This Year
- TLS $47.80
- XNCR $23.31
- Revenue Next Year
- TLS $26.19
- XNCR N/A
- P/E Ratio
- TLS N/A
- XNCR N/A
- Revenue Growth
- TLS N/A
- XNCR N/A
- 52 Week Low
- TLS $1.83
- XNCR $6.92
- 52 Week High
- TLS $7.48
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- TLS 54.15
- XNCR 73.35
- Support Level
- TLS $6.71
- XNCR $11.17
- Resistance Level
- TLS $7.42
- XNCR $15.37
- Average True Range (ATR)
- TLS 0.43
- XNCR 0.90
- MACD
- TLS -0.08
- XNCR 0.19
- Stochastic Oscillator
- TLS 46.63
- XNCR 84.29
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.